不同抗肿瘤治疗方式对PD-L1表达的影响及相关机制

The effect of different anti-tumor treatments on the expression of PD-L1 and related mechanisms

程序性死亡受体-1/配体-L1(PD-1/PD-L1)抑制剂作为免疫治疗的新型药物,常与放化疗、靶向治疗等联合应用到各种恶性肿瘤的治疗中,目前认为PD-L1表达率可预测PD-L1抑制剂疗效。而不同的抗肿瘤治疗会对PD-L1的表达产生不同的影响,因此明确不同抗肿瘤治疗方式对PD-L1表达水平的影响以及相关机制显得十分重要。本文总结了不同抗肿瘤治疗方式对PD-L1表达的影响以及其发生机制,指出了肿瘤患者在接受免疫治疗前以及治疗期间,需行二次甚至多次活检来明确肿瘤组织的PD-L1表达情况,以协助临床医师判断是否可以施行联合免疫治疗,帮助患者有更好的生存获益。

In recent years,programmed death receptor-1/ligand-L1(PD-L1)inhibitors are often used in combination with radiotherapy,chemotherapy,and targeted therapy in the treatment of various malignant tumors.It is currently believed that the expression rate of PD-L1 can predict PD-L1 efficacy of L1 inhibitor.This paper reviewed many domestic and foreign studies on the effects and mechanisms of different anti-tumor treatments on PD-L1 expression and found that there are differences in the effects of different treatment options on PD-L1 expression and the mechanisms involved.It is pointed out that before and during treatment,tumor patients need to undergo two or even multiple biopsies to confirm the expression of PD-L1 in tumor tissues,so as to assist clinicians in determining whether to combine immunotherapy,so that patients can have better survival benefits.